ITGB7 and Miyoshi myopathy: For example, OPC-415, an investigational therapy targeting ITGB7, is currently being evaluated in a Phase I/II clinical trial (NCT04649073) for patients with R/R MM, specifically those with MMG49 antigen-positive myeloma cells.